Vertex registers Phase 3b trial comparing povetacicept and sibeprenlimab in IgA nephropathy
The single-arm study will assess patient experience with self-injected povetacicept after a switch from sibeprenlimab in adults with IgA nephropathy.
Vertex Pharmaceuticals had one new trial registration this week.
- A Phase 3b, open-label, single-arm study (NCT07890909) will compare patient experience with povetacicept delivered via autoinjector to sibeprenlimab delivered via prefilled syringe in adults with Immunoglobulin A Nephropathy. The study aims to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe, and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy.1 The study is listed as not yet recruiting, with an estimated enrollment of 40 participants1 and an estimated start date of 2026-10-23.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.